Please use this identifier to cite or link to this item:
|Title:||Bioequivalence of doxazosin slow release tablets : a pilot study|
Zammit, Marie Clare
Zarb Adami, Maurice
Azzopardi, Lilian M.
|Keywords:||Drugs -- Therapeutic equivalency|
Doxazosin -- Analysis
Doxazosin -- Therapeutic use
High performance liquid chromatography -- Methodology
|Publisher:||University of Malta. Department of Pharmacy|
|Citation:||Attard, A., Cilia, M., Zammit, M. C., Wirth, F., Coleiro, B., Zarb Adami, M.,…Serracino-Inglott, A. (2010, March). Bioequivalence of doxazosin slow release tablets: a pilot study. Poster session presented at the 7th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Valletta, Malta.|
|Abstract:||A poster presentation regarding a pilot study on the bioequivalence of doxazosin slow release tablets. Introduction: Bioequivalence studies are carried out to compare the systemic exposure profile of a test drug product to that of a reference product. Doxazosin is a potent quinazoline derivative and is effective for the treatment of hypertension and benign prostatic hyperplasia. Aim: To carry out a pilot bioequivalence study to assess comparative bioavailability between test product, doxazosin mesylate 8mg slow release tablets and reference product, Cardura®XL 8mg tablets.|
|Appears in Collections:||Scholarly Works - FacM&SPha|
Files in This Item:
|Bioequivalence_of_doxazosin_slow_release_tablets_a_pilot_study_2010.pdf||1.1 MB||Adobe PDF||View/Open|
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.